The ARGO clinical trial protocol has been published in the “New Treatments for Keratoconus” Special Issue of International Ophthalmology.
The publication is open access and available at https://link.springer.com/article/10.1007/s10792-022-02628-4.
The manuscript includes exhaustive information on the ARGO clinical trial design and research protocol, which is targeting to validate #theranostics for personalized and precision corneal cross-linking for treating keratoconus.
Regensight is a startup Company committed in the dissemination of the clinical trial design for the benefit of the entire medical community and the patients they serve. This is a part of the ethical mandate, mission and vision statement of our Company.